Matches in SemOpenAlex for { <https://semopenalex.org/work/W2998806808> ?p ?o ?g. }
- W2998806808 endingPage "106876" @default.
- W2998806808 startingPage "106876" @default.
- W2998806808 abstract "This post hoc analysis of six randomized, double-blind, Phase II and III studies evaluated efficacy and safety of adjunctive perampanel (2-12 mg/day) in adolescent patients (aged ≥12 to ≤17 years) with uncontrolled partial-onset seizures, with or without secondarily generalized (SG) seizures, or primary generalized tonic-clonic (PGTC) seizures.Adolescent patients from Studies 304 (NCT00699972), 305 (NCT00699582), 306 (NCT00700310), 335 (NCT01618695), 235 (NCT01161524), and 332 (NCT01393743) were included. Efficacy assessments (split by seizure type) included median percent change in seizure frequency per 28 days from baseline and seizure-freedom rates. Safety assessments (all seizure types combined) included monitoring of treatment-emergent adverse events (TEAEs).The Safety Analysis Set included 372 adolescent patients (placebo, n = 114; perampanel, n = 258); the Full Analysis Set included 346 patients with partial-onset seizures (placebo, n = 103; perampanel, n = 243), of whom 125 experienced SG seizures during baseline (placebo, n = 37; perampanel, n = 88), and 22 with PGTC seizures (placebo, n = 9; perampanel, n = 13). Compared with placebo, perampanel 8 and 12 mg/day conferred greater median percent reductions in seizure frequency per 28 days for partial-onset seizures (18.0% vs 35.9% and 53.8% [both P < 0.01]) and SG seizures (24.4% vs 72.8% [P < 0.001] and 57.8% [P < 0.01]), and greater seizure-freedom rates (partial-onset: 7.8% vs 13.2% and 11.8% [not statistically significant]; SG: 8.1% vs 40.7% [P < 0.001] and 41.7% [P < 0.01]). For PGTC seizures, and compared with placebo, perampanel 8 mg/day was also associated with greater median percent reductions in seizure frequency per 28 days (29.8% vs 88.0%) and greater seizure-freedom rates (11.1% vs 23.1%). Treatment-emergent adverse events were reported in 76 (66.7%) placebo- and 192 (74.4%) perampanel-treated patients (most common: dizziness, somnolence, headache, and nasopharyngitis). Serious TEAEs occurred in 5 (4.4%) placebo- and 11 (4.3%) perampanel-treated patients.Adjunctive perampanel was efficacious and generally well tolerated in adolescent patients with partial-onset, SG, or PGTC seizures and represents a potentially beneficial treatment option for adolescents with uncontrolled epilepsy." @default.
- W2998806808 created "2020-01-23" @default.
- W2998806808 creator A5015881339 @default.
- W2998806808 creator A5018971404 @default.
- W2998806808 creator A5020477271 @default.
- W2998806808 creator A5023502731 @default.
- W2998806808 creator A5025122018 @default.
- W2998806808 creator A5040378349 @default.
- W2998806808 creator A5063400633 @default.
- W2998806808 creator A5089756778 @default.
- W2998806808 date "2020-03-01" @default.
- W2998806808 modified "2023-10-01" @default.
- W2998806808 title "Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of six randomized studies" @default.
- W2998806808 cites W1498758291 @default.
- W2998806808 cites W1551373999 @default.
- W2998806808 cites W1588850953 @default.
- W2998806808 cites W1750723157 @default.
- W2998806808 cites W1862220344 @default.
- W2998806808 cites W1975378514 @default.
- W2998806808 cites W1982112616 @default.
- W2998806808 cites W1993609519 @default.
- W2998806808 cites W2005586141 @default.
- W2998806808 cites W2038975845 @default.
- W2998806808 cites W2063394491 @default.
- W2998806808 cites W2071065489 @default.
- W2998806808 cites W2083402697 @default.
- W2998806808 cites W2083402915 @default.
- W2998806808 cites W2132146185 @default.
- W2998806808 cites W2135007397 @default.
- W2998806808 cites W2135808877 @default.
- W2998806808 cites W2145520222 @default.
- W2998806808 cites W2163482216 @default.
- W2998806808 cites W2180981774 @default.
- W2998806808 cites W2217932554 @default.
- W2998806808 cites W2335372547 @default.
- W2998806808 cites W2367812079 @default.
- W2998806808 cites W2400720743 @default.
- W2998806808 cites W2551888831 @default.
- W2998806808 cites W2769648968 @default.
- W2998806808 cites W2772236704 @default.
- W2998806808 cites W2796976931 @default.
- W2998806808 cites W4249020671 @default.
- W2998806808 cites W4253561025 @default.
- W2998806808 cites W62288012 @default.
- W2998806808 doi "https://doi.org/10.1016/j.yebeh.2019.106876" @default.
- W2998806808 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31954998" @default.
- W2998806808 hasPublicationYear "2020" @default.
- W2998806808 type Work @default.
- W2998806808 sameAs 2998806808 @default.
- W2998806808 citedByCount "26" @default.
- W2998806808 countsByYear W29988068082020 @default.
- W2998806808 countsByYear W29988068082021 @default.
- W2998806808 countsByYear W29988068082022 @default.
- W2998806808 countsByYear W29988068082023 @default.
- W2998806808 crossrefType "journal-article" @default.
- W2998806808 hasAuthorship W2998806808A5015881339 @default.
- W2998806808 hasAuthorship W2998806808A5018971404 @default.
- W2998806808 hasAuthorship W2998806808A5020477271 @default.
- W2998806808 hasAuthorship W2998806808A5023502731 @default.
- W2998806808 hasAuthorship W2998806808A5025122018 @default.
- W2998806808 hasAuthorship W2998806808A5040378349 @default.
- W2998806808 hasAuthorship W2998806808A5063400633 @default.
- W2998806808 hasAuthorship W2998806808A5089756778 @default.
- W2998806808 hasBestOaLocation W29988068081 @default.
- W2998806808 hasConcept C118552586 @default.
- W2998806808 hasConcept C126322002 @default.
- W2998806808 hasConcept C142724271 @default.
- W2998806808 hasConcept C15744967 @default.
- W2998806808 hasConcept C168563851 @default.
- W2998806808 hasConcept C197934379 @default.
- W2998806808 hasConcept C204787440 @default.
- W2998806808 hasConcept C27081682 @default.
- W2998806808 hasConcept C2778186239 @default.
- W2998806808 hasConcept C2780836401 @default.
- W2998806808 hasConcept C3018162438 @default.
- W2998806808 hasConcept C42219234 @default.
- W2998806808 hasConcept C67761136 @default.
- W2998806808 hasConcept C71924100 @default.
- W2998806808 hasConceptScore W2998806808C118552586 @default.
- W2998806808 hasConceptScore W2998806808C126322002 @default.
- W2998806808 hasConceptScore W2998806808C142724271 @default.
- W2998806808 hasConceptScore W2998806808C15744967 @default.
- W2998806808 hasConceptScore W2998806808C168563851 @default.
- W2998806808 hasConceptScore W2998806808C197934379 @default.
- W2998806808 hasConceptScore W2998806808C204787440 @default.
- W2998806808 hasConceptScore W2998806808C27081682 @default.
- W2998806808 hasConceptScore W2998806808C2778186239 @default.
- W2998806808 hasConceptScore W2998806808C2780836401 @default.
- W2998806808 hasConceptScore W2998806808C3018162438 @default.
- W2998806808 hasConceptScore W2998806808C42219234 @default.
- W2998806808 hasConceptScore W2998806808C67761136 @default.
- W2998806808 hasConceptScore W2998806808C71924100 @default.
- W2998806808 hasFunder F4320322148 @default.
- W2998806808 hasLocation W29988068081 @default.
- W2998806808 hasLocation W29988068082 @default.
- W2998806808 hasOpenAccess W2998806808 @default.
- W2998806808 hasPrimaryLocation W29988068081 @default.
- W2998806808 hasRelatedWork W2060121528 @default.